Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm

JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms

(2014) S. Leah Etheridge et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Red blood cells mediate the onset of thrombosis in the ferric chloride murine model

(2013) J. D. Barr et al.   BLOOD

JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia

(2013) C. M. Hobbs et al.   BLOOD

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN 

(2013) S. Hasan et al.   BLOOD

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management

(2012) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway

(2012) M. De Grandis et al.   BLOOD

Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo

(2012) Marie-Luise von Brühl et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy

(2012) Marie-Catherine Rouzaud et al.   THROMBOSIS AND HAEMOSTASIS

Prognostic Factors and Models in Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis

(2011) Francesco Passamonti   Clinical Lymphoma Myeloma & Leukemia

Mechanisms underlying FeCl3-induced arterial thrombosis

(2011) A. ECKLY et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice

(2010) C. Marty et al.   BLOOD

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

(2010) H. Akada et al.   BLOOD

Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells

(2010) Ann Mullally et al.   CANCER CELL

Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review

(2009) Federico Lussana et al.   THROMBOSIS RESEARCH

Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence andJAK2 V617F allele burden

(2008) Eduardo Arellano-Rodrigo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia

(2008) A. Carobbio et al.   BLOOD

Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients

(2008) F. Santilli et al.   BLOOD

Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

(2008) P. D. Ziakas   HAEMATOLOGICA

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

(2008) V. De Stefano et al.   HAEMATOLOGICA

Is JAK2 V617F mutation more than a diagnostic index?

(2008) Issa J. Dahabreh et al.   LEUKEMIA RESEARCH